New treatment for brittle bone disease found

August 9, 2013
New treatment for brittle bone disease found

A new treatment for children with brittle bone disease has been developed by the University of Sheffield and Sheffield Children's Hospital.

The study of the new treatment for children with the fragile bone disease Osteogenesis Imperfecta was published this week in the world's leading general medical journal, The Lancet.

This is the first study to clearly demonstrate that the use of the medicine risedronate can not only reduce the risk of fracture in children with brittle bones but also have rapid action - the curves for begin to diverge after only 6 weeks of treatment.

Nick Bishop, Professor of Paediatric Bone Disease at the University of Sheffield, said: "We wanted to show that the use of risedronate could significantly impact on children's lives by reducing fracture rates - and it did.

"The fact that this medicine can be given by mouth at home (other similar medicines are given by a drip in hospital) makes it family-friendly."

The study, funded by the Alliance for Better Bone Health, trialled children with Osteogenesis Imperfecta aged 4-15 years and showed that oral reduced the risk of first and recurrent clinical fractures and that the drug was generally well tolerated.

Explore further: Pioneering research will assess the effects of obesity on bone development

More information: To read the published article in The Lancet, titled Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial, visit The Lancet. www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961091-0/fulltext

Related Stories

Teriparatide injections improve pedicle bone quality

May 2, 2013

(HealthDay)—Daily injection of teriparatide significantly reduces the incidence of pedicle screw (PS) loosening at one year following surgery to correct degenerative spondylolisthesis in osteoporotic postmenopausal women, ...

Gene discoveries give hope against 'Brittle bone' disease

May 8, 2013

(HealthDay)—Mutations in a gene involved in bone development appear to cause certain severe forms of bone loss, a finding that could lead to new therapies for the common bone-thinning disorder osteoporosis, researchers ...

Recommended for you

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Mosquitoes, Zika and biotech regulation

September 19, 2016

In a new Policy Forum article in Science, NC State professor Jennifer Kuzma argues that federal authorities are missing an opportunity to revise outdated regulatory processes not fit for modern innovations in biotechnology, ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.